New combo therapy aims to shrink hard-to-treat liver tumors
NCT ID NCT06859684
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new first-line treatment for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer that cannot be removed by surgery. The treatment combines chemotherapy directly into the liver artery (HAIC) with two drugs: durvalumab (an immunotherapy) and lenvatinib (a targeted therapy). The goal is to see if this triple approach shrinks tumors better than current standard treatments. About 25 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DURVALUMAB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spirulina's secret protein may shield the liver during surgery
- New drug cocktail aims to outsmart untreatable bile duct cancer
- AI could spot liver cancer types and predict survival without needle biopsy
- New drug cocktails aim to stop bile duct cancer return after surgery
- New cocktail of Liver-Directed chemo and immunotherapy targets deadly bile duct cancer
- Anti-Inflammatory drug may boost cancer therapy in bile duct cancer